Collegium Pharmaceutical Stock News

STOUGHTON, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of the Top Places to Work in Massachusetts in The Boston Globe s 14th annual employee-based survey.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL)s stock price gapped down prior to trading on Monday . The stock had previously closed at $18.53, but opened at $17.99. Collegium Pharmaceutical shares last traded at $17.95, with a volume of 550 shares changing hands. A number of equities research analysts recently commented on the stock. TheStreet upgraded shares of []

Millennium Management LLC grew its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 77.5% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 134,737 shares of the specialty pharmaceutical companys stock after acquiring an additional 58,847 shares during the period. Millennium Management LLCs holdings in Collegium Pharmaceutical were []

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares reached a new 52-week low during trading on Friday . The company traded as low as $17.63 and last traded at $17.72, with a volume of 998 shares trading hands. The stock had previously closed at $18.53. COLL has been the subject of a number of recent analyst reports. TheStreet [] The post Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 52-Week Low at $17.63 appeared first on ETF Daily News .

California State Teachers Retirement System lowered its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 6.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,520 shares of the specialty pharmaceutical company’s stock after selling 3,238 shares during the period. California […]

Equities analysts expect that Collegium Pharmaceutical, Inc. (NASDAQ:COLL) will announce earnings per share of $1.04 for the current quarter, Zacks reports. Four analysts have issued estimates for Collegium Pharmaceutical’s earnings. The highest EPS estimate is $1.09 and the lowest is $0.96. Collegium Pharmaceutical reported earnings of $0.20 per share in the same quarter last year, […]

Collegium Pharmaceutical (NASDAQ:COLL) had its price target upped by Needham & Company LLC from $26.00 to $28.00 in a research note published on Monday, Analyst Price Targets reports. They currently have a buy rating on the specialty pharmaceutical companys stock. Other research analysts also recently issued reports about the stock. HC Wainwright decreased their target []

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) gapped up before the market opened on Monday after Needham & Company LLC raised their price target on the stock from $26.00 to $28.00. The stock had previously closed at $19.48, but opened at $20.50. Needham & Company LLC currently has a buy rating on the stock. Collegium Pharmaceutical []

STOUGHTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Companys common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized by its Board of Directors in August 2021. Upon completion of this ASR, Collegium will have $52.2 million remaining under the authorization.

Northern Trust Corp reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 432,362 shares of the specialty pharmaceutical companys stock after selling 6,059 shares during the period. []

STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, toda

STOUGHTON, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, toda

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2021 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STOUGHTON, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, anno